A Phase 1, randomized, 1-day 5-period crossover study in adults with type 1 diabetes on CSII investigated whether pain is dependent on the site and/or depth of infusion of ultra rapid lispro (URLi) excipients.

Forty participants (mean age 40.5 years; BMI 27.5) were randomized to 1 of 5 infusion site sequences consisting of the abdomen, arm, thigh, and buttock (6 mm cannula depth) , and abdomen (9 mm depth) . Basal infusion of sodium citrate, treprostinil, and magnesium chloride in diluent was initiated (1 U/h) and 15 unit-equivalent boluses were given at 3, 6, and 9 h after basal initiation. Participants rated local infusion site pain perception by the 0-100 mm validated visual analog scale (VAS) at 5 min before bolus and 1 and 15 min post bolus.

An increased VAS score was occasionally reported at 1 min post bolus, more frequently for the arm. Most scores were ≤10 mm (little to no discomfort) while 7 of 577 were >45 mm (generally considered clinically meaningful pain) . VAS score distributions were similar between cannula depths (Figure) . After 15 min, scores were similar to pre bolus. No participants discontinued the study.

Local infusion site discomfort after infusion of URLi excipients was reported by a subset of participants; it was transient, tolerable, and dependent on infusion site. Given differences among sites within individuals, patients may consider changing infusion site if they experience discomfort.


D. A. Ignaut: None. T. Fukuda: Employee; Eli Lilly and Company. B. Ramanjineyulu: None. M. Ermer: None. M. S. Stoffel: None. E. Zijlstra: Speaker’s Bureau; Gan & Lee Pharmaceuticals, Novo Nordisk. D. Paavola: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company.


Eli Lilly and Company

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.